The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AGN-PC-00CRPM     5-amino-1-cyclopropyl-7- (3,5...

Synonyms: AG-K-03289, SureCN1387460, ACMC-20c8ks, CTK4A7080, AR-1G7013, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of sparfloxacin


High impact information on sparfloxacin


Chemical compound and disease context of sparfloxacin


Biological context of sparfloxacin


Anatomical context of sparfloxacin

  • Despite their anticipated markedly higher intracellular human neutrophil (PMN) concentrations, RP 59500 and sparfloxacin activities in medium alone were equal to or greater than those inside PMNs against almost all strains [19].
  • These data suggest that a once-daily, 3-day regimen of sparfloxacin is effective and generally well tolerated in the treatment of acute uncomplicated urinary tract infections [20].
  • The unidirectional fluxes across cell monlayers grown on permeable filters indicated that a net secretion of sparfloxacin and vinblastine occurred across Caco-2 cells [21].
  • Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages [22].
  • The mechanism of intestinal secretion of the difluorinated quinolone sparfloxacin was investigated with the epithelial cell line Caco-2 and was compared to that of the P-glycoprotein (P-gp) substrate vinblastine [21].

Associations of sparfloxacin with other chemical compounds


Gene context of sparfloxacin


Analytical, diagnostic and therapeutic context of sparfloxacin


  1. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Amankwa, K., Krishnan, S.C., Tisdale, J.E. Clin. Pharmacol. Ther. (2004) [Pubmed]
  2. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. De Sarro, A., De Sarro, G. Current medicinal chemistry. (2001) [Pubmed]
  3. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Lalande, V., Truffot-Pernot, C., Paccaly-Moulin, A., Grosset, J., Ji, B. Antimicrob. Agents Chemother. (1993) [Pubmed]
  4. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones. Pan, X.S., Hamlyn, P.J., Talens-Visconti, R., Alovero, F.L., Manzo, R.H., Fisher, L.M. Antimicrob. Agents Chemother. (2002) [Pubmed]
  5. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Azoulay-Dupuis, E., Vallee, E., Veber, B., Bedos, J.P., Bauchet, J., Pocidalo, J.J. Antimicrob. Agents Chemother. (1992) [Pubmed]
  6. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Kang, J., Wang, L., Chen, X.L., Triggle, D.J., Rampe, D. Mol. Pharmacol. (2001) [Pubmed]
  7. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Goldstein, E.J., Citron, D.M., Nesbit, C.A. Diabetes Care (1996) [Pubmed]
  8. Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy. Shandil, R.K., Jayaram, R., Kaur, P., Gaonkar, S., Suresh, B.L., Mahesh, B.N., Jayashree, R., Nandi, V., Bharath, S., Balasubramanian, V. Antimicrob. Agents Chemother. (2007) [Pubmed]
  9. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. Zhi, C., Long, Z.Y., Manikowski, A., Comstock, J., Xu, W.C., Brown, N.C., Tarantino, P.M., Holm, K.A., Dix, E.J., Wright, G.E., Barnes, M.H., Butler, M.M., Foster, K.A., LaMarr, W.A., Bachand, B., Bethell, R., Cadilhac, C., Charron, S., Lamothe, S., Motorina, I., Storer, R. J. Med. Chem. (2006) [Pubmed]
  10. Efficacy and safety of single oral dose sparfloxacin vs ciprofloxacin in acute gonococcal urethritis in males. A multicentre international study. Moi, H., Morel, P., Gianotti, B., Barlow, D., Phillips, I., Jean, C. Drugs (1995) [Pubmed]
  11. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Clement, J.J., Tanaka, S.K., Alder, J., Vojtko, C., Beyer, J., Hensey, D., Ramer, N., McDaniel, D., Chu, D.T. Antimicrob. Agents Chemother. (1994) [Pubmed]
  12. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Masuda, N., Takahashi, Y., Otsuki, M., Ibuki, E., Miyoshi, H., Nishino, T. Antimicrob. Agents Chemother. (1996) [Pubmed]
  13. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Kenny, G.E., Cartwright, F.D. Antimicrob. Agents Chemother. (1996) [Pubmed]
  14. Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes. Michelet, C., Avril, J.L., Arvieux, C., Jacquelinet, C., Vu, N., Cartier, F. Antimicrob. Agents Chemother. (1997) [Pubmed]
  15. Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. Stahlmann, R., Zippel, U., Förster, C., Schwabe, R., Shakibaei, M., Merker, H.J., Borner, K. Antimicrob. Agents Chemother. (1998) [Pubmed]
  16. Clinical pharmacokinetics of sparfloxacin. Shimada, J., Nogita, T., Ishibashi, Y. Clinical pharmacokinetics. (1993) [Pubmed]
  17. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Entenza, J.M., Blatter, M., Glauser, M.P., Moreillon, P. Antimicrob. Agents Chemother. (1994) [Pubmed]
  18. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Montero, C., Mateu, G., Rodriguez, R., Takiff, H. Antimicrob. Agents Chemother. (2001) [Pubmed]
  19. Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium. Herrera-Insúa, I., Jacques-Palaz, K., Murray, B.E., Rakita, R.M. Antimicrob. Agents Chemother. (1996) [Pubmed]
  20. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Henry, D., Ellison, W., Sullivan, J., Mansfield, D.L., Magner, D.J., Dorr, M.B., Talbot, G.H. Antimicrob. Agents Chemother. (1998) [Pubmed]
  21. Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors. Cormet-Boyaka, E., Huneau, J.F., Mordrelle, A., Boyaka, P.N., Carbon, C., Rubinstein, E., Tomé, D. Antimicrob. Agents Chemother. (1998) [Pubmed]
  22. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Rastogi, N., Labrousse, V., Goh, K.S., De Sousa, J.P. Antimicrob. Agents Chemother. (1991) [Pubmed]
  23. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Cagni, A., Chuard, C., Vaudaux, P.E., Schrenzel, J., Lew, D.P. Antimicrob. Agents Chemother. (1995) [Pubmed]
  24. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E. Antimicrob. Agents Chemother. (2003) [Pubmed]
  25. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium. Mitsuyama, J., Itoh, Y., Takahata, M., Okamoto, S., Yasuda, T. Antimicrob. Agents Chemother. (1992) [Pubmed]
  26. In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic. Yun, H.J., Min, Y.H., Lim, J.A., Kang, J.W., Kim, S.Y., Kim, M.J., Jeong, J.H., Choi, Y.J., Kwon, H.J., Jung, Y.H., Shim, M.J., Choi, E.C. Antimicrob. Agents Chemother. (2002) [Pubmed]
  27. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Fuchs, P.C., Barry, A.L., Pfaller, M.A., Allen, S.D., Gerlach, E.H. Antimicrob. Agents Chemother. (1991) [Pubmed]
  28. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Kocagöz, T., Hackbarth, C.J., Unsal, I., Rosenberg, E.Y., Nikaido, H., Chambers, H.F. Antimicrob. Agents Chemother. (1996) [Pubmed]
  29. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Pan, X.S., Fisher, L.M. Antimicrob. Agents Chemother. (1997) [Pubmed]
  30. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis. Tankovic, J., Bachoual, R., Ouabdesselam, S., Boudjadja, A., Soussy, C.J. J. Antimicrob. Chemother. (1999) [Pubmed]
  31. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance. Richard, M.P., Aguado, A.G., Mattina, R., Marre, R. J. Antimicrob. Chemother. (1998) [Pubmed]
  32. Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Shimizu, A., Miyoshi, M., Sugie, M., Ueyama, J., Yamaguchi, T., Sasaki, T., Takagi, K., Jin, M., Miyamoto, K., Tsuji, A., Hasegawa, T. Eur. J. Pharmacol. (2004) [Pubmed]
  33. Pharmacokinetics of sparfloxacin in patients with renal impairment. Fillastre, J.P., Montay, G., Bruno, R., Etienne, I., Dhib, M., Vivier, N., Le Roux, Y., Guimart, C., Gay, G., Schott, D. Antimicrob. Agents Chemother. (1994) [Pubmed]
  34. The role of fluoroquinolones in tuberculosis today. Berning, S.E. Drugs (2001) [Pubmed]
  35. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Goa, K.L., Bryson, H.M., Markham, A. Drugs (1997) [Pubmed]
  36. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials. Liu, W., Liu, Q.F., Perkins, R., Drusano, G., Louie, A., Madu, A., Mian, U., Mayers, M., Miller, M.H. Antimicrob. Agents Chemother. (1998) [Pubmed]
WikiGenes - Universities